As the CRO flies
Successful treatment development relationships rely on the ability of contract research organisations to bring their skills to the table – and pharma’s willingness to let that happen
PharmaTimes Magazine Archive
Magazine highlights
View more from the latest edition
Biosimilar adalimumab: a landmark for NHS medicines optimisation
The implications of adalimumab’s European patent expiry
Precision medicine: optimising access
The new models that could help the industry encourage the adoption of personalised treatments
Precision medicine: overcoming cost challenges
Personalised treatments may be well-established in pharma now, but high prices continue to stymie their reach
Company focus: VistaGen
CEO Shawn Singh explains how his company hopes to change the treatment landscape for depression with an alternative to ketamine
Organs on a chip
This new innovation could be a paradigm shift for clinical trials, but it’s not without issues
RWE meets social media
We speak to Orbital Media’s CEO Peter Brady to find out how his company is taking a new approach to gathering data on how medicines fare in the real world
The future of multichannel
Wunderman Health EMEA lead Mo Zouina and Wunderman Health Global client lead Cassandra Sinclair give their views on the new technologies and practices that could change marketing in the near future
